The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known
as “restenosis”. This phenomenon is due to vessel remodeling/recoil in case of no-stent …

The field of interventional cardiology has significantly evolved over 40 years by overcoming
several challenges. The introduction of first-generation drug-eluting stents significantly …

Over the past 40 years, the safety and efficacy of percutaneous coronary intervention has
dramatically improved by overcoming several challenges. The introduction of drug-eluting …

The efferocytosis defect is regarded as a pivotal event of atherosclerosis. The failure to clear
apoptotic cells in atherosclerotic plaques under vascular stents causes a failure to resolve …

Coronary artery disease (CAD) remains one of the most important causes of morbidity and
mortality worldwide, and the availability of percutaneous or surgical revascularization …

Background In-stent restenosis (ISR), especially for neoatherosclerosis, is still a major
problem of percutaneous coronary intervention (PCI) even in the drug-eluting stent (DES) …

The recognition that obstructive disease of the epicardial coronary arteries, causing
ischaemic heart disease, can be treated with a percutaneous coronary intervention (PCI) …

Background: Clinical and morphological factors associated with lipidic versus calcified
neoatherosclerosis within second-generation drug-eluting stents and the impact of lipidic …

Aims: In-stent restenosis (ISR) is an important cause of drug-eluting stent (DES) failure and
target vessel revascularisation. In this study we aimed to evaluate differences between early …

Aims Delayed healing and endothelial dysfunction may occur with drug-eluting stents (DES),
promoting accelerated infiltration of lipids in the neointima and development of …